As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
In an effort to stave off costly production setbacks for otherwise profitable drugs, Big Pharma is turning to a wider manufacturing footprint and cutting-edge technology as companies struggle to meet demand for therapies that treat diseases like cancer, …